Skip to content

The latest company news, press releases, and resources about Servier and everything our company has to offer.

Advanced Search
  • servier logo
     
    12.09.2019
    Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
  • servier logo
     
    12.04.2019
    Servier Showcases Robust Presence at ASH 2019
  • servier logo
     
    11.22.2019
    Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma
  • servier logo
     
    10.27.2019
    Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
  • servier logo
     
    10.09.2019
    Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference
Media Contacts

Servier Media Relations
us2mediarelations@servier.com

Subscribe